2008-07-02 15:01:16 - www.companiesandmarkets.com adds new report - Panacos Pharmaceuticals Inc - Premium Company Profile

www.companiesandmarkets.com/Summary-Company-Profile/Panacos-Phar ..
Introduction

Panacos Pharmaceuticals is a development stage biotechnology company specialized in developing antiviral products for the treatment of patients with HIV infection. The company’s lead drug candidate, bevirimat (formerly PA-457) is an HIV maturation inhibitor and also a promising new antiviral class discovered by the company’s researchers.



Scope

Contains corporate strategy, value chain presence and SWOT Analysis
Provides detailed

business description, segment analysis, 5-year financial trends, key products and key competitors
Includes information on suppliers/ partners, shareholding structure and key employees with biographies


Highlights

Panacos Pharmaceuticals’ lead product candidate, bevirimat (PA-457), is the first in a new class of oral HIV therapeutics under development called maturation inhibitors and currently in the Phase IIb stage of development. Its product pipeline also includes HIV Fusion Inhibitor for the treatment of HIV infection and PA-1050040 for HIV treatment.



The company derives all of its revenues from the research grants contract with National Institutes of Health (NIH) along with research funding from the University of North Carolina related to the development of certain product candidates for the treatment of HIV infections.



Panacos Pharmaceuticals’ major contributor to sales growth out to 2010 will be sales of bevirimat, which is expected to launch in the year 2010. The product is forecast to record sales of $15 million in the year of its launch.



Reasons to Purchase

Access all the important information and analysis on the company in a single report
Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company’s adjusted five year financial data along with key ratios and market capitalization